View ValuationShaperon 将来の成長Future 基準チェック /06現在、 Shaperonの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長24.7%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Apr 17Shaperon Inc. announced that it has received KRW 8.6 billion in fundingOn April 15, 2026, Shaperon Inc. has closed the transaction.お知らせ • Apr 09Shaperon Inc. announced that it expects to receive KRW 8.6 billion in fundingShaperon Inc. announces a private placement to issue Series 1 Bearer-type interest-bearing unsecured private placement convertible bonds for gross proceeds of KRW 8,600,000,000 on April 7, 2026. Expected closing date of the offering is April 15, 2026. Interest rate of the Notes is 0% and Maturity of the Bonds is April 15, 2031. Conversion price is KRW 1,685. Conversion period starts from April 15, 2027 and ends on March 15, 2031. GVA Coven-14 General Private Investment Trust advised by Samsung Securities Co., Ltd. for KRW 800,000,000, GVA Coven-0 General Private Investment Trust advised by Samsung Securities Co., Ltd for KRW 750,000,000.お知らせ • Mar 12Shaperon Inc., Annual General Meeting, Mar 27, 2026Shaperon Inc., Annual General Meeting, Mar 27, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 174-10, jagok-ro, gangnam-gu, seoul South KoreaNew Risk • Nov 22New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 53% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Revenue has declined by 87% over the past year. Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Revenue is less than US$1m (₩12m revenue, or US$8.0k). Minor Risk Market cap is less than US$100m (₩80.1b market cap, or US$54.5m).お知らせ • Nov 14Shaperon Inc. Attends 7th Inflammasome Therapeutics Summit in BostonShaperon Inc. announced that it attended the 7th Inflammasome Therapeutics Summit held in Boston, Massachusetts, from November 4-6, 2025. During the event, CEO Dr. Seungyong Seong delivered a keynote presentation highlighting the company's latest clinical and preclinical achievements in the development of inflammasome-modulating therapies for atopic dermatitis and alopecia areata. The Inflammaome Therapeutics Summit is a leading global conference dedicated to advances in inflammasome research and drug development. Shaperon's participation and keynote presentation underscore the growing recognition of its GPCR19-based drug discovery platform as an emerging technology with the potential to reshape the treatment landscape for inflammatory and autoimmune diseases. In his keynote, Dr. Seong presented the company's progress on GPCR19-targeted inflammasome modulation, a novel therapeutic strategy designed to control inflammation at its upstream initiation phase. Unlike conventionalNLRP3 inhibitors that act downstream, Shaperon's approach regulates the formation of the inflammasome complex itself, confirming the broad applicability of its inflammasome-targeted technology. Shaperon's topical candidate NuGel, the world's first GPCR19 agonist for atopic dermatitis, demonstrated positive efficacy and safety results in Phase 2b Part 1 clinical trials. The company also shared new preclinical data across acne, rosacea, and diabetic foot ulcers, confirming the broad applicabilityof its inflammasome- target technology. Shaperon's proprietary AI-powered drug discovery platform integrates multi-parametric modeling to predict target suitability, pharmacokinetic properties and toxicity profiles, enabling faster and more reliable development decisions. One of its AI-derived candidates, Nualeratine, showed a 74% higher hair regrowth rate in preclinical models of autoimmune alopecia compared to competing compounds.お知らせ • Nov 06Shaperon Inc. has completed a Follow-on Equity Offering in the amount of KRW 24.860387 billion.Shaperon Inc. has completed a Follow-on Equity Offering in the amount of KRW 24.860387 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 16,049,314 Price\Range: KRW 1549 Discount Per Security: KRW 30.98 Transaction Features: Rights Offeringお知らせ • Aug 19Shaperon Inc. has filed a Follow-on Equity Offering in the amount of KRW 30.0426 billion.Shaperon Inc. has filed a Follow-on Equity Offering in the amount of KRW 30.0426 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 16,100,000 Price\Range: KRW 1866 Discount Per Security: KRW 37.32 Transaction Features: Rights OfferingNew Risk • Aug 19New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩16b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue has declined by 86% over the past year. Revenue is less than US$1m (₩30m revenue, or US$21k). Minor Risk Market cap is less than US$100m (₩60.9b market cap, or US$43.8m).分析記事 • Aug 01Is Shaperon (KOSDAQ:378800) In A Good Position To Deliver On Growth Plans?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...New Risk • May 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩17b free cash flow). Revenue has declined by 92% over the past year. Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Revenue is less than US$1m (₩18m revenue, or US$13k). Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Market cap is less than US$100m (₩114.4b market cap, or US$82.9m).New Risk • Mar 21New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩17b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩17b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue has declined by 92% over the past year. Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Revenue is less than US$1m (₩18m revenue, or US$12k). Minor Risk Market cap is less than US$100m (₩97.1b market cap, or US$66.3m).New Risk • Mar 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue has declined by 36% over the past year. Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Revenue is less than US$1m (₩91m revenue, or US$63k). Minor Risk Market cap is less than US$100m (₩101.4b market cap, or US$70.0m).お知らせ • Mar 06Shaperon Inc., Annual General Meeting, Mar 25, 2025Shaperon Inc., Annual General Meeting, Mar 25, 2025, at 10:00 Tokyo Standard Time. Location: auditorium, 419, bongeunsa-ro, gangnam-gu, seoul South KoreaNew Risk • Jan 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 31% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Revenue has declined by 36% over the past year. Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Revenue is less than US$1m (₩91m revenue, or US$63k). Minor Risk Market cap is less than US$100m (₩121.3b market cap, or US$83.2m).分析記事 • Dec 20Is Shaperon (KOSDAQ:378800) In A Good Position To Deliver On Growth Plans?Just because a business does not make any money, does not mean that the stock will go down. For example, although...分析記事 • Sep 02We're Keeping An Eye On Shaperon's (KOSDAQ:378800) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...New Risk • Jul 08New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 31% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Revenue has declined by 84% over the past year. Revenue is less than US$1m (₩215m revenue, or US$156k). Minor Risks Less than 3 years of financial data is available. Shareholders have been diluted in the past year (31% increase in shares outstanding). Market cap is less than US$100m (₩45.3b market cap, or US$32.9m).New Risk • May 29New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Revenue has declined by 84% over the past year. Revenue is less than US$1m (₩215m revenue, or US$158k). Minor Risks Less than 3 years of financial data is available. Market cap is less than US$100m (₩52.8b market cap, or US$38.7m).分析記事 • Apr 12Is Shaperon (KOSDAQ:378800) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...New Risk • Apr 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 89% over the past year. Revenue is less than US$1m (₩215m revenue, or US$156k). Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (8.2% average weekly change). Market cap is less than US$100m (₩66.6b market cap, or US$48.2m).お知らせ • Mar 20Shaperon Enrolls its First Patient in Phase 2 U.S. Clinical Trial for Atopic Dermatitis Therapy 'Nugel'Shaperon Inc. announced the enrollment of the first patient in the Phase 2 clinical trial for Nugel, its therapy for Atopic Dermatitis. This milestone marks the start of a crucial phase in Shaperon's effort to advance treatment for patients globally. With FDA approval secured for the Global Phase 2 Clinical Trials (IND) of Nugel in September 2023, Shaperon is dedicated to evaluating its efficacy in improving the Eczema Area Severity Index (EASI) across a diverse cohort of 210 patients with mild to moderate atopic dermatitis. Employing a rigorous double-blind, placebo-controlled methodology, the trial is anticipated to conclude by the first half of 2026. Market research forecasts indicate a robust growth of over 8.7%, projecting the global atopic dermatitis market to reach $19.1 billion by 2030. Presently, patients rely on steroids and FDA-approved medications, yet there remains a pressing need for novel drugs due to their adverse effects and limited efficacy. Of particular note, more than 70% of patients exhibit positive responses to the biomarker discovered during Shaperon's phase 2 clinical trials in Korea, categorized as "A type A atopic patients." This treatment, distinguished by its superior safety and efficacy compared to existing JAK inhibitors or PDE4 inhibitors in the market, has garnered attention at U.S. and European forums. Shaperon has already initiated patent applications for this biomarker, enabling tailored treatments for patients showing exceptional responses to Nugel. Nugel represents a paradigm shift in atopic dermatitis therapy as the world's first inflammation control drug targeting 'GPCR19' action. Its unique mechanism of action, exclusive to immune-related cells, offers minimal side effects while effectively addressing inflammatory pathways. Beyond atopic dermatitis, Nugel holds promise for treating a spectrum of skin conditions, further underscoring its potential impact on global healthcare.New Risk • Jul 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Market cap is less than US$100m (₩114.7b market cap, or US$89.5m). このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Shaperon は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測KOSDAQ:A378800 - アナリストの将来予測と過去の財務データ ( )KRW Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/2026281-15,543-13,867-13,499N/A12/31/2025228-15,528-14,906-14,501N/A9/30/2025179-14,589-16,984-16,879N/A6/30/202512-13,279-15,924-15,735N/A3/31/202530-13,581-16,409-16,267N/A12/31/202418-14,903-17,301-16,737N/A9/30/202491-15,905-16,461-14,102N/A6/30/202491-15,345-16,092-13,697N/A3/31/2024215-14,999-15,727-13,386N/A12/31/2023215-12,403-14,942-13,010N/A9/30/2023142-11,548-11,223-10,886N/A12/31/20222,000-10,673-8,139-7,952N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: A378800の予測収益成長が 貯蓄率 ( 3.1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: A378800の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: A378800の収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: A378800の収益がKR市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: A378800の収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: A378800の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/10 22:58終値2026/06/10 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Shaperon Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 17Shaperon Inc. announced that it has received KRW 8.6 billion in fundingOn April 15, 2026, Shaperon Inc. has closed the transaction.
お知らせ • Apr 09Shaperon Inc. announced that it expects to receive KRW 8.6 billion in fundingShaperon Inc. announces a private placement to issue Series 1 Bearer-type interest-bearing unsecured private placement convertible bonds for gross proceeds of KRW 8,600,000,000 on April 7, 2026. Expected closing date of the offering is April 15, 2026. Interest rate of the Notes is 0% and Maturity of the Bonds is April 15, 2031. Conversion price is KRW 1,685. Conversion period starts from April 15, 2027 and ends on March 15, 2031. GVA Coven-14 General Private Investment Trust advised by Samsung Securities Co., Ltd. for KRW 800,000,000, GVA Coven-0 General Private Investment Trust advised by Samsung Securities Co., Ltd for KRW 750,000,000.
お知らせ • Mar 12Shaperon Inc., Annual General Meeting, Mar 27, 2026Shaperon Inc., Annual General Meeting, Mar 27, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 174-10, jagok-ro, gangnam-gu, seoul South Korea
New Risk • Nov 22New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 53% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Revenue has declined by 87% over the past year. Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Revenue is less than US$1m (₩12m revenue, or US$8.0k). Minor Risk Market cap is less than US$100m (₩80.1b market cap, or US$54.5m).
お知らせ • Nov 14Shaperon Inc. Attends 7th Inflammasome Therapeutics Summit in BostonShaperon Inc. announced that it attended the 7th Inflammasome Therapeutics Summit held in Boston, Massachusetts, from November 4-6, 2025. During the event, CEO Dr. Seungyong Seong delivered a keynote presentation highlighting the company's latest clinical and preclinical achievements in the development of inflammasome-modulating therapies for atopic dermatitis and alopecia areata. The Inflammaome Therapeutics Summit is a leading global conference dedicated to advances in inflammasome research and drug development. Shaperon's participation and keynote presentation underscore the growing recognition of its GPCR19-based drug discovery platform as an emerging technology with the potential to reshape the treatment landscape for inflammatory and autoimmune diseases. In his keynote, Dr. Seong presented the company's progress on GPCR19-targeted inflammasome modulation, a novel therapeutic strategy designed to control inflammation at its upstream initiation phase. Unlike conventionalNLRP3 inhibitors that act downstream, Shaperon's approach regulates the formation of the inflammasome complex itself, confirming the broad applicability of its inflammasome-targeted technology. Shaperon's topical candidate NuGel, the world's first GPCR19 agonist for atopic dermatitis, demonstrated positive efficacy and safety results in Phase 2b Part 1 clinical trials. The company also shared new preclinical data across acne, rosacea, and diabetic foot ulcers, confirming the broad applicabilityof its inflammasome- target technology. Shaperon's proprietary AI-powered drug discovery platform integrates multi-parametric modeling to predict target suitability, pharmacokinetic properties and toxicity profiles, enabling faster and more reliable development decisions. One of its AI-derived candidates, Nualeratine, showed a 74% higher hair regrowth rate in preclinical models of autoimmune alopecia compared to competing compounds.
お知らせ • Nov 06Shaperon Inc. has completed a Follow-on Equity Offering in the amount of KRW 24.860387 billion.Shaperon Inc. has completed a Follow-on Equity Offering in the amount of KRW 24.860387 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 16,049,314 Price\Range: KRW 1549 Discount Per Security: KRW 30.98 Transaction Features: Rights Offering
お知らせ • Aug 19Shaperon Inc. has filed a Follow-on Equity Offering in the amount of KRW 30.0426 billion.Shaperon Inc. has filed a Follow-on Equity Offering in the amount of KRW 30.0426 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 16,100,000 Price\Range: KRW 1866 Discount Per Security: KRW 37.32 Transaction Features: Rights Offering
New Risk • Aug 19New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩16b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue has declined by 86% over the past year. Revenue is less than US$1m (₩30m revenue, or US$21k). Minor Risk Market cap is less than US$100m (₩60.9b market cap, or US$43.8m).
分析記事 • Aug 01Is Shaperon (KOSDAQ:378800) In A Good Position To Deliver On Growth Plans?Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
New Risk • May 30New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩17b free cash flow). Revenue has declined by 92% over the past year. Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Revenue is less than US$1m (₩18m revenue, or US$13k). Minor Risks Share price has been volatile over the past 3 months (9.4% average weekly change). Market cap is less than US$100m (₩114.4b market cap, or US$82.9m).
New Risk • Mar 21New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩17b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩17b free cash flow). Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue has declined by 92% over the past year. Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Revenue is less than US$1m (₩18m revenue, or US$12k). Minor Risk Market cap is less than US$100m (₩97.1b market cap, or US$66.3m).
New Risk • Mar 12New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue has declined by 36% over the past year. Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Revenue is less than US$1m (₩91m revenue, or US$63k). Minor Risk Market cap is less than US$100m (₩101.4b market cap, or US$70.0m).
お知らせ • Mar 06Shaperon Inc., Annual General Meeting, Mar 25, 2025Shaperon Inc., Annual General Meeting, Mar 25, 2025, at 10:00 Tokyo Standard Time. Location: auditorium, 419, bongeunsa-ro, gangnam-gu, seoul South Korea
New Risk • Jan 16New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 31% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Revenue has declined by 36% over the past year. Shareholders have been substantially diluted in the past year (31% increase in shares outstanding). Revenue is less than US$1m (₩91m revenue, or US$63k). Minor Risk Market cap is less than US$100m (₩121.3b market cap, or US$83.2m).
分析記事 • Dec 20Is Shaperon (KOSDAQ:378800) In A Good Position To Deliver On Growth Plans?Just because a business does not make any money, does not mean that the stock will go down. For example, although...
分析記事 • Sep 02We're Keeping An Eye On Shaperon's (KOSDAQ:378800) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
New Risk • Jul 08New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 31% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Revenue has declined by 84% over the past year. Revenue is less than US$1m (₩215m revenue, or US$156k). Minor Risks Less than 3 years of financial data is available. Shareholders have been diluted in the past year (31% increase in shares outstanding). Market cap is less than US$100m (₩45.3b market cap, or US$32.9m).
New Risk • May 29New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Revenue has declined by 84% over the past year. Revenue is less than US$1m (₩215m revenue, or US$158k). Minor Risks Less than 3 years of financial data is available. Market cap is less than US$100m (₩52.8b market cap, or US$38.7m).
分析記事 • Apr 12Is Shaperon (KOSDAQ:378800) In A Good Position To Invest In Growth?Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
New Risk • Apr 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue has declined by 89% over the past year. Revenue is less than US$1m (₩215m revenue, or US$156k). Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (8.2% average weekly change). Market cap is less than US$100m (₩66.6b market cap, or US$48.2m).
お知らせ • Mar 20Shaperon Enrolls its First Patient in Phase 2 U.S. Clinical Trial for Atopic Dermatitis Therapy 'Nugel'Shaperon Inc. announced the enrollment of the first patient in the Phase 2 clinical trial for Nugel, its therapy for Atopic Dermatitis. This milestone marks the start of a crucial phase in Shaperon's effort to advance treatment for patients globally. With FDA approval secured for the Global Phase 2 Clinical Trials (IND) of Nugel in September 2023, Shaperon is dedicated to evaluating its efficacy in improving the Eczema Area Severity Index (EASI) across a diverse cohort of 210 patients with mild to moderate atopic dermatitis. Employing a rigorous double-blind, placebo-controlled methodology, the trial is anticipated to conclude by the first half of 2026. Market research forecasts indicate a robust growth of over 8.7%, projecting the global atopic dermatitis market to reach $19.1 billion by 2030. Presently, patients rely on steroids and FDA-approved medications, yet there remains a pressing need for novel drugs due to their adverse effects and limited efficacy. Of particular note, more than 70% of patients exhibit positive responses to the biomarker discovered during Shaperon's phase 2 clinical trials in Korea, categorized as "A type A atopic patients." This treatment, distinguished by its superior safety and efficacy compared to existing JAK inhibitors or PDE4 inhibitors in the market, has garnered attention at U.S. and European forums. Shaperon has already initiated patent applications for this biomarker, enabling tailored treatments for patients showing exceptional responses to Nugel. Nugel represents a paradigm shift in atopic dermatitis therapy as the world's first inflammation control drug targeting 'GPCR19' action. Its unique mechanism of action, exclusive to immune-related cells, offers minimal side effects while effectively addressing inflammatory pathways. Beyond atopic dermatitis, Nugel holds promise for treating a spectrum of skin conditions, further underscoring its potential impact on global healthcare.
New Risk • Jul 24New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Market cap is less than US$100m (₩114.7b market cap, or US$89.5m).